CTTI Recommendations Developed to Improve Engagement in Mobile Clinical Trials

George Clinical is proud to have been involved in developing the recently announced recommendations by the Clinical Trial Transformation Initiative (CTTI): The Recommendations for Engaging Patients and Sites in Mobile Clinical Trials. The recommendations, to which George Clinical contributed as a member on the expert committee, aim to help research organizations, sponsors, and other stakeholders […]

Read More

June 1st, 2019

George Clinical Expands Asia-Pacific Footprint with New Location in the Philippines

SYDNEY, May 29, 2019 – George Clinical, a global scientifically-backed clinical research organization (CRO), has again expanded its extensive Asia-Pacific footprint through the opening of a new office in the Philippines.  The office is based in the capital city, Manila and compliments the organization’s growing list of global locations.   The opening of this office […]

Read More

May 29th, 2019

George Clinical Awarded Taiwanese Drug License

 SYDNEY, May 15, 2019 – George Clinical, a global scientifically-backed clinical research organization (CRO), has significantly expanded its capabilities in Taiwan having been granted a license to import drugs into the country for clinical trials on behalf of sponsors.  The development will be particularly helpful for small to mid-sized clinical trial clients who do not […]

Read More

May 14th, 2019

EPS International and George Clinical Form Strategic Partnership for the Asia-Pacific Region

Sydney, Australia, April 24, 2019 – EPS International Holdings Co., Ltd. (HQ: Tokyo, Japan; Representative Director and President: Hisashi Tanaka; “EPSI” hereafter) and George Clinical Pty Ltd (HQ: Sydney, Australia; Executive Chairman: Glenn Kerkhof; “George Clinical” hereafter) announced today that they have reached an agreement on a strategic partnership that will enhance their combined service offerings […]

Read More

April 24th, 2019

George Clinical Client Noxopharm Announces Chemotherapy Enhancement Program Expansion

Noxopharm, a clinical-stage Australian drug development company currently working with George Clinical, is seeking to establish Veyonda®, an innovative dosage formulation of the experimental anti-cancer drug idronoxil, as “an essential adjunct to all forms of radiotherapy in the treatment of prostate cancer, both late-stage and early-stage prostate cancer,” according to an announcement last week. Through […]

Read More

April 20th, 2019

George Clinical Scientific Leader Named Chief Medical Officer of OneOncology

OneOncology, a national partnership of community oncologists, recently announced that Lee Schwartzberg, MD, FACP, a member of the George Clinical scientific leadership committee, has been named Chief Medical Officer (CMO). According to OneOncology, the CMO position “provides a dynamic link between OneOncology and its physician partners, demonstrating the shared, foundational commitment to a physician-driven, data-driven, technology-powered, […]

Read More

April 17th, 2019

Late Breaking Clinical Trial CREDENCE Webcast to Stream this Month

ISN World Congress of Nephrology will be live streaming “Late Breaking Clinical Trials” from WCN 2019. The purpose of the webcast is to give the worldwide nephrology community in-depth understanding of three major nephrology studies, including the CREDENCE study for which George Clinical plays a critical role.   The session will be streamed live from […]

Read More

April 5th, 2019

George Clinical Strengthens Asia-Pacific Presence with New Singapore Location

George Clinical, a global scientifically backed clinical research organization, (CRO) has expanded its footprint in Asia with the addition of a new presence in Singapore. The new office and entity in Singapore, which was established in July, were requisites for George Clinical to act as a local clinical trial sponsor for the firm’s international client […]

Read More

April 2nd, 2019
Dr. Maria Ali

George Clinical Promotes Maria Ali to the Role of Chief Medical Officer

OVERLAND PARK, KS, March 6, 2019 George Clinical, a leading Asia-Pacific based clinical research organization (CRO) with global capabilities, today announced that Dr. Maria Ali has been promoted to Chief Medical Officer to be based out of Raleigh, North Carolina. This move further solidifies the strategic growth of George Clinical throughout North America and recognizes […]

Read More

March 6th, 2019

George Clinical Congratulates Parent Company The George Institute For Global Health For Securing $12 Million To Tackle Worlds Biggest Killers

[Sydney, Australia] George Clinical congratulates its parent company, The George Institute for Global Health for securing $12 million from the National Health and Medical Research Council (NHMRC), Australia’s peak funding body for medical research. These grants will support The Institute’s scientific leaders to improve the lives of people living with chronic kidney disease, septic shock […]

Read More

February 12th, 2019

Add George Clinical to your network